Porcine parvovirus 5a, methods of use and vaccine

Abstract

The present invention provides novel nucleotides sequences, protein sequences, immunogenic compositions, vaccines, and methods that relate to making and using new porcine parvovirus 5A (PPV5A) that infects, inter alia, domestic swine. The compositions and methods provide for the detection of infections by said new virus, monitoring genetic changes in the viral sequences in wild and domestic animals and herds, and making and using novel vaccines for protecting animals from infection by the virus.

What is claimed is: 
     
         1 . An isolated polynucleotide, comprising a polynucleotide
 a) having the nucleic acid sequence of SEQ ID NO:1;   b) having a nucleic acid sequence that encodes a polypeptide of SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4;   c) having a nucleic acid sequence 80% identical to SEQ ID NO:1, which encodes a polypeptide having a biological or immunologically-effective activity of a polypeptide of SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4;   d) that is a fragment of the nucleic acid sequence of SEQ ID NO:1, comprising at least 30 contiguous nucleotide sequences of SEQ ID NO:1, or   e) that is a fragment of the nucleic acid sequence of SEQ ID NO:1, comprising at least 30 contiguous nucleotide sequences of SEQ ID NO:1, and which encode an immunologically-effective activity of an amino acid sequence of SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4.   
     
     
         2 . An isolated polypeptide, comprising a polypeptide
 a) having the amino acid sequence of SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4;   b) having an amino acid sequence 80% identical to SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4 and having a biological or immunologically-effective activity of a polypeptide encoded by SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4;   c) that is a fragment of the amino acid sequence of SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4, comprising at least 15 contiguous amino acids of SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4;   d) that is a fragment of the amino acid sequence of SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4, comprising at least 15 contiguous amino acids of SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4, and having an immunologically-effective activity; or   e) a protein fragment that is encoded by a polynucleotide that comprises at least 15, nucleotides included in the sequences of nucleotides 87-1967 of SEQ ID NO:1, nucleotides 1975-2844 of SEQ ID NO:1, or nucleotides 2845-5547 of SEQ ID NO:1.   
     
     
         3 . An isolated  porcine parvovirus  5A (PPV5A), comprising
 a) a nucleic acid sequence of SEQ ID NO:1, or   b) a nucleic acid sequence 80% identical to SEQ ID NO:1, which encodes a polypeptide having a biological or immunologically-effective activity of a polypeptide of SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4.   
     
     
         4 . The PPV5A of  claim 3 , comprising an attenuated, non-virulent form of a PPV5A. 
     
     
         5 . A vaccine for treating or preventing an infection by a virulent PPV5A, comprising a killed or attenuated form of a PPV5A of  claim 3 . 
     
     
         6 . A vaccine for treating or preventing an infection by a virulent PPV5A, comprising a subunit of a killed or attenuated form of a PPV5A of  claim 3 . 
     
     
         7 . A vaccine of  claim 6 , wherein the subunit is a capsid protein of SEQ ID NO:4. 
     
     
         8 . A vaccine of  claim 6 , wherein the subunit is an immunologically-effective fragment of a polypeptide of SEQ ID NO:4. 
     
     
         9 . An immunogenic preparation comprising an immunologically-effective amount of a polypeptide of  claim 2 , and a pharmaceutical- or veterinary-acceptable carrier, excipient or diluent. 
     
     
         10 . A method of generating an immune response in a mammal, comprising administering an immunologically-effective amount of a PPV5A of  claim 3 . 
     
     
         11 . A method of generating an immune response in a mammal, comprising administering an immunologically-effective amount of a polypeptide of  claim 2 . 
     
     
         12 . A method of generating an immune response in a mammal, comprising administering an immunologically-effective amount of a vaccine of  claim 5 . 
     
     
         13 . A method of generating an immune response in a mammal, comprising administering an immunologically-effective amount of a vaccine of  claim 6 . 
     
     
         14 . A method of generating an immune response in a mammal, comprising administering an immunologically-effective amount of a vaccine of  claim 7 . 
     
     
         15 . A method of  claim 10 , wherein the mammal is a swine, and the immune response provides protective immunity to disease caused by PPV5A infection. 
     
     
         16 . A method of  claim 11 , wherein the mammal is a swine, and the immune response provides protective immunity to disease caused by PPV5A infection. 
     
     
         17 . A method of  claim 12 , wherein the mammal is a swine, and the immune response provides protective immunity to disease caused by PPV5A infection. 
     
     
         18 . A method of  claim 13 , wherein the mammal is a swine, and the immune response provides protective immunity to disease caused by PPV5A infection. 
     
     
         19 . A method of  claim 14 , wherein the mammal is a swine, and the immune response provides protective immunity to disease caused by PPV5A infection. 
     
     
         20 . An isolated antibody that specifically binds to a PPV5A polypeptide encoded by a  porcine parvovirus  5A polynucleotide having a sequence of SEQ ID NO:1, said polypeptide having an amino acid sequence of SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4, and wherein said antibody does not bind to a polypeptide encoded by a different  parvovirus.    
     
     
         21 . A method of identifying the presence of PPV5A in a biological sample, comprising
 a) contacting the biological sample with an antibody of  claim 21 ,   b) detecting the formation of a complex between the antibody and a PPV5A polypeptide,   wherein the presence of said complex indicates the presence of PPV5A in the biological sample.   
     
     
         22 . A vector or plasmid that comprises a polynucleotide of  claim 1 . 
     
     
         23 . A host cell comprising a vector of  claim 22 . 
     
     
         24 . A hybridoma that expresses an antibody of  claim 20 . 
     
     
         25 . A diagnostic kit for identifying the presence of PPV5A in a biological sample, comprising
 a) an antibody of  claim 21 , and   b) reagents for detecting the formation of a complex between the antibody and a PPV5A polypeptide.   
     
     
         26 . An immunogenic kit, comprising
 a) at least one immunogenic PPV5A peptide which is effective to immunize an animal against at least one disease associated with PPV5A infection;   b) at least one carrier or adjuvant molecule;   c) a container for packaging the immunogenic composition;   d) a set of printed instructions; and   e) a dispenser capable of administering the immunogenic composition to an animal.   
     
     
         27 . An immunogenic kit of  claim 26 , further comprising at least one immunogenic protein which is effective to immunize said animal against at least one other  porcine  pathogenic virus or bacteria which causes a disease associated with an infection with said virus or bacteria.